-
What Prescription Drug Pricing Can Learn From Value-Based Care Models
As pharma becomes part of the value-based revolution, there are several lessons that can be learned from the ongoing development of value-based care.
-
2023 Likely To Be a Crucial Year for Pharma—and Insurers
2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It’s likely to be a year of experimentation for payers – and defensiveness for drug makers.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
MedCity Influencers, BioPharma, Legal
Biden’s New Executive Order Could Usher in an Era of Fair and Equitable Drug Pricing
By leveraging its large membership, Medicare could by embracing value-based contracting significantly influence the pharmaceutical market, pitting competing drugs against each other, or encouraging pharmaceutical makers to figure out ways to deliver drugs more cheaply.
-
Aduhelm’s loss is a win for value-based drug pricing
Value-based pricing could have shown us with more certainty the real level of effectiveness of Aduhelm. Maybe it is worth paying something for; and value-based contracts are the only way to figure that out.